Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

KOL Strategy

- PMLiVE

Roche’s Tecentriq combo scores in first-line melanoma

Plans to file treatment with health authorities on strength of data

- PMLiVE

Gilead owes BMS millions after losing Yescarta patent infringement trial

Jury found Gilead's CAR-T infringed on exclusive patent

- PMLiVE

Novartis ditches oral asthma drug after disappointing phase 3 readout

Bad news for Gossamer’s would-be rival DP2 antagonist

- PMLiVE

UPDATED: Senate officially confirms Stephen Hahn as FDA commissioner

Final Senate vote was 72 to 18 in favour of the radiation oncology expert

- PMLiVE

GCI Health opens new office in Hong Kong

Will be led by newly appointed director Yvonne Yeung

- PMLiVE

Horizon looks bright as FDA panel backs eye drug teprotumumab

First alternative to surgery for proptosis

- PMLiVE

Novel endpoints in the digital age

Redesigning the goalposts

- PMLiVE

Brexit nears as Conservatives sweep to victory in election

British pharma association 'looks forward to working with the new Government'

- PMLiVE

House Democrats finally pass landmark drug pricing bill

Proposed legislation met with harsh criticism from pharma industry

- PMLiVE

FDA grants surprise OK to Sarepta’s DMD therapy after earlier rejection

Initially had concerns about infection risks and kidney toxicity

- PMLiVE

AZ, Daiichi Sankyo strengthen case for HER2 candidate

Will rival Roche's HER2 franchise if approved

- PMLiVE

Biologic patent exclusivity scrapped in new US trade deal

Drugmakers dealt a blow in latest trade negotiations

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links